ReviewJournal of psychiatry & neuroscience : JPN2005
Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder.
Review in Journal of psychiatry & neuroscience : JPN, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 86 citations in OpenAlex.
- Acute shift in glutamate concentrations following experimentally induced panic with cholecystokinin tetrapeptide--a 3T-MRS study in healthy subjects.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2013Trial
- Case Report: Panic attack induced by albendazole in a post-PCI patient.Frontiers in psychiatry · 2026Article
- A molecularly defined brain circuit module for regulating panic-like defensive state.Nature communications · 2025Article
- Brain Mechanisms Underlying Panic Attack and Panic Disorder.Neuroscience bulletin · 2024Review
- Cytokine profile in drug-naïve panic disorder patients.Translational psychiatry · 2022Article
- Glutamic Acid Decarboxylase 1 Gene Methylation and Panic Disorder Severity: Making the Connection by Brain Gray Matter Volume.Frontiers in psychiatry · 2022Article
- Anticonvulsant and antipsychotic medications in the pharmacotherapy of panic disorder: a structured review.Therapeutic advances in psychopharmacology · 2021Review
- Pediatric Migraine and Academics.Current pain and headache reports · 2020Review
- An open-label, flexible dose adaptive study evaluating the efficacy of vortioxetine in subjects with panic disorder.Annals of general psychiatry · 2018Article
- The relation between GAD1 and PTSD symptoms: Shared risk for depressive symptoms.Psychiatry research · 2017Article
- Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry · 2017Review
- Pseudopheochromocytoma induced by anxiolytic withdrawal.European journal of medical research · 2014Article
- Hippocampal hyperexcitability underlies enhanced fear memories in TgNTRK3, a panic disorder mouse model.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2013Article
- Gender differences in associations of glutamate decarboxylase 1 gene (GAD1) variants with panic disorder.PloS one · 2012Article
- Experimental panic provocation in healthy man-a translational role in anti-panic drug development?Dialogues in clinical neuroscience · 2011Review
- Biomarkers in development of psychotropic drugs.Dialogues in clinical neuroscience · 2011Review
- The GABA transporter 1 (SLC6A1): a novel candidate gene for anxiety disorders.Journal of neural transmission (Vienna, Austria : 1996) · 2009Article
- PHARMACOLOGICAL TREATMENTS FOR TINNITUS: NEW AND OLD.Drugs of the future · 2009Article
- Phenelzine causes an increase in brain ornithine that is prevented by prior monoamine oxidase inhibition.Neurochemical research · 2008Article
- Critical role of the 65-kDa isoform of glutamic acid decarboxylase in consolidation and generalization of Pavlovian fear memory.Learning & memory (Cold Spring Harbor, N.Y.) · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
gamma-Aminobutyric acid (GABA) is the most important inhibitory neurotransmitter in the central nervous system (CNS). It exerts its rapid inhibitory action mostly through GABA(A) receptors, which are targets for benzodiazepines, barbiturates, neuroactive steroids and distinct anticonvulsive agents. There is considerable evidence that dysfunction of GABA(A) receptors or dysregulation of GABA concentrations in the CNS (or both) plays an important role in the pathophysiology of panic disorder. Currently, benzodiazepines are the only drugs directly targeting the GABA(A) receptors that are approved for the treatment of anxiety disorders. Because of their well-known anxiolytic effects, they are widely used in this setting, but side effects limit their use in long-term treatment. The question of whether drugs that selectively increase GABA concentrations in the CNS could improve symptoms of anxiety has been discussed. Recent investigations by our group have demonstrated that enhancement of endogenous GABA (through blockade of GABA transaminase by vigabatrin or through inhibition of GABA transporters by tiagabine) exerts anxiolytic effects on experimentally induced panic. Our studies in healthy volunteers have shown that both compounds lead to a significant reduction in panic symptoms elicited by cholecystokinin-tetrapeptide. Moreover, benzodiazepine-like effects on the activity of the hypothalamic-pituitary-adrenal axis have been observed in association with vigabatrin treatment. Small open studies in patients with panic disorder also showed an improvement in panic and anxiety with both compounds. This review summarizes our recent research on the effects of selective GABAergic treatment in experimentally induced panic and outlines the possible role of compounds targeting the GABA binding site of the GABA(A)-benzodiazepine receptor for the treatment of panic and anxiety.
Indexed as
Identifiers
15944741PMC1089777W2139938825What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.